Medicine and Dentistry
Hypertrophic Obstructive Cardiomyopathy
100%
Hypertrophic Cardiomyopathy
90%
Transthyretin
60%
Placebo
42%
Systematic Review
36%
Heart Amyloidosis
36%
Muscle Resection
36%
Meta-Analysis
33%
Amyloid Cardiomyopathy
33%
Hazard Ratio
33%
Heart Left Ventricle Ejection Fraction
30%
Atrial Fibrillation
29%
Echocardiography
28%
Sudden Cardiac Death
27%
Aortic Stenosis
26%
Ventricular Outflow Tract
23%
Mavacamten
23%
Heart Failure
23%
Odds Ratio
22%
Implantable Automatic Defibrillator
22%
Cohort Analysis
20%
Bicuspid Aortic Valve
19%
Percutaneous Aortic Valve Replacement
19%
Observational Study
19%
Prevalence
18%
Heart Disease
18%
Cardiomyopathy
18%
Heart Surgery
17%
New York Heart Association Class
17%
Oxygen Consumption
17%
Obstruction
17%
Amino Terminal Sequence
16%
Cardiac Magnetic Resonance Imaging
15%
Cardiac Myosin
15%
Tafamidis
15%
Disease
15%
Aortic Valve Replacement
14%
Atrial Flutter
14%
Exercise
14%
Stress Echocardiography
14%
Apoplexy
13%
Biological Marker
13%
ATTR Amyloidosis
13%
All Cause Mortality
13%
Heart Left Ventricle Outflow Tract Obstruction
13%
Symptom
13%
Amyloidosis
12%
Aortic Valve
12%
Ejection Fraction
12%
Coronary Artery Disease
12%
Pharmacology, Toxicology and Pharmaceutical Science
Hypertrophic Obstructive Cardiomyopathy
73%
Transthyretin
71%
Hypertrophic Cardiomyopathy
66%
Placebo
56%
Cardiomyopathy
48%
Amyloid
38%
ATTR Amyloidosis
33%
Heart Amyloidosis
30%
Heart Failure
30%
Amyloidosis
29%
Atrial Fibrillation
29%
Mavacamten
27%
Cardiac Myosin
20%
Polyneuropathy
18%
Adverse Event
18%
Sudden Cardiac Death
16%
Disease
16%
Obstruction
16%
Prevalence
15%
Heart Atrium Flutter
14%
Biological Marker
14%
Clinical Trial
13%
Symptom
13%
Tafamidis
12%
Brain Natriuretic Peptide
12%
Combination Therapy
11%
Heart Disease
10%
Randomized Controlled Trial
10%
Cohort Study
10%
Observational Study
9%
Neuropathy
9%
All Cause Mortality
8%
Natriuretic Factor
8%
Cerebrovascular Accident
8%
Pharmacotherapy
7%
Troponin I
7%
Heart Atrium Arrhythmia
6%
Aortic Stenosis
6%
Hospital Mortality
6%
Heart Outflow Tract Obstruction
6%
New-Onset Atrial Fibrillation
6%
Inotersen
6%
Heart Arrhythmia
6%
Randomized Clinical Trial
5%
Deterioration
5%
Heart Left Ventricle Outflow Tract Obstruction
5%
Thrombocytopenia
5%
Congestive Heart Failure
5%
Diabetic Neuropathy
5%
Myocardial Disease
5%
Keyphrases
Hypertrophic Obstructive Cardiomyopathy
67%
Hypertrophic Cardiomyopathy
44%
Aficamten
40%
Meta-analysis
33%
Confidence Interval
25%
Atrial Fibrillation
25%
Systematic Meta-analysis
20%
Left Ventricular Ejection Fraction
19%
Septal Myectomy
18%
Transthyretin Amyloidosis
17%
Odds Ratio
15%
Cardiac Amyloidosis
14%
Placebo
14%
Left Ventricular Outflow Tract Gradient
12%
Polyneuropathy
11%
Implantable Defibrillator
11%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
10%
Myosin Activation
9%
Readmission
9%
Transthyretin Amyloid Cardiomyopathy
9%
Safety Efficacy
9%
Surgical Intervention
9%
Left Ventricular Outflow Tract Obstruction (LVOTO)
9%
Sudden Cardiac Death
8%
Heart Failure
7%
Randomized Controlled Trial
7%
In-hospital Mortality
7%
Septal Reduction Therapy
7%
ATTR-CM
7%
Radiation-induced Heart Disease
7%
New-onset Atrial Fibrillation
6%
Long-term Mortality
6%
Transthyretin
6%
Hazard Ratio
6%
Nutritional Status
6%
Sudden Cardiac Death Risk
6%
Nationwide Readmissions Database
6%
Mitral Valve Repair
6%
Cardiopulmonary Exercise Testing
6%
Inotersen
6%
Exercise Capacity
6%
All-cause Mortality
6%
Cardiac Biomarkers
6%
Randomized Trial
5%
Light Chain Amyloidosis
5%
Symptom Burden
5%
Health-related Quality of Life
5%
Standard of Care
5%
Mavacamten
5%
Sudden Cardiac Death Prevention
5%